G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease.
Valeria Rachela Villella,Andrea Venerando,Giorgio Cozza,Speranza Esposito,Eleonora Ferrari,Eleonora Ferrari,Romina Monzani,Romina Monzani,Mara C. Spinella,Mara C. Spinella,Vasilis Oikonomou,Giorgia Renga,Antonella Tosco,Federica Rossin,Stefano Guido,Marco Silano,Enrico Garaci,Yu-Kai Chao,Christian Grimm,Alessandro Luciani,Luigina Romani,Mauro Piacentini,Valeria Raia,Guido Kroemer,Luigi Maiuri,Luigi Maiuri +25 more
TL;DR: A primordial role for CFTR is unveiled as a central hub orchestrating gliadin activities and a novel therapeutic option for celiac disease is identified.
Journal ArticleDOI
Trial Watch—Immunostimulation with cytokines in cancer therapy
Erika Vacchelli,Fernando Aranda,Norma Bloy,Aitziber Buqué,Isabelle Cremer,Alexander M.M. Eggermont,Wolf Hervé Fridman,Jitka Fucikova,Jérôme Galon,Radek Spisek,Laurence Zitvogel,Guido Kroemer,Lorenzo Galluzzi +12 more
TL;DR: Recent preclinical and clinical advances in the use of some cytokines as immunostimulatory agents in oncological indications are discussed.
Journal ArticleDOI
3,4-Dimethoxychalcone induces autophagy through activation of the transcription factors TFE3 and TFEB.
Guo Chen,Wei Xie,Jihoon Nah,Allan Sauvat,Peng Liu,Federico Pietrocola,Valentina Sica,Didac Carmona-Gutierrez,Andreas Zimmermann,Tobias Pendl,Jelena Tadic,Martina Bergmann,Sebastian J. Hofer,Lana Domuz,Lana Domuz,Sylvie Lachkar,Maria Markaki,Nektarios Tavernarakis,Nektarios Tavernarakis,Junichi Sadoshima,Frank Madeo,Oliver Kepp,Guido Kroemer +22 more
TL;DR: The results suggest that 3,4‐DC is a novel CRM with a previously unrecognized mode of action, which induced autophagy in vitro and in mouse organs, mediated Autophagy‐dependent cardioprotective effects, and improved the efficacy of anticancer chemotherapy in vivo.
Journal ArticleDOI
Mutant MyoD Lacking Cdc2 Phosphorylation Sites Delays M-Phase Entry
Lionel A. Tintignac,Valentina Sirri,Marie Pierre Leibovitch,Yann Lécluse,Maria Castedo,Didier Métivier,Guido Kroemer,Serge A. Leibovitch +7 more
TL;DR: Evidence that MyoD plays a pivotal role at the G2/M transition by controlling the expression of p21Waf1/Cip1 (p21), which is believed to regulate cyclin B-Cdc2 kinase activity in G2, is provided.
Journal ArticleDOI
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.
Christophe Massard,Jean-Charles Soria,D. Alan Anthoney,A Proctor,Angela Scaburri,M. A. Pacciarini,Bernard Laffranchi,Cinzia Pellizzoni,Guido Kroemer,Jean-Pierre Armand,Rastilav Balheda,Chris Twelves +11 more
TL;DR: PHA-793887 induces severe, dose-related hepatic toxicity, which was not predicted by pre-clinical models and currently precludes its further clinical development.